Insider Selling: Liquidia (NASDAQ:LQDA) Insider Sells $262,528.64 in Stock

Liquidia Corporation (NASDAQ:LQDA) insider Rajeev Saggar sold 9,218 shares of the company’s stock in a transaction on Monday, October 12th. The shares were sold at an average price of $28.48, for a total transaction of $262,528.64. Following the completion of the transaction, the insider owned 126,368 shares in the company, valued at approximately $3,598,960.64. This represents a 6.80% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Rajeev Saggar also recently made the following trade(s):

• On Monday, August 17th, Rajeev Saggar sold 29,534 shares of Liquidia stock. The shares were sold at an average price of $76.84, for a total transaction of $2,269,392.56.
• On Wednesday, August 19th, Rajeev Saggar sold 50,000 shares of Liquidia stock. The shares were sold at an average price of $74.06, for a total transaction of $3,703,000.00.

Liquidia Price Performance

Shares of LQDA opened at $34.78 on Friday. The company’s 50-day moving average is $61.21 and its 200-day moving average is $61.73. The company has a debt-to-equity ratio of 0.63, a current ratio of 2.31 and a quick ratio of 2.12. The firm has a market capitalization of $3.11 billion, a PE ratio of 24.77 and a beta of 0.61. Liquidia Corporation has a fifty-two week low of $21.94 and a fifty-two week high of $93.61.

Liquidia (NASDAQ:LQDA) last announced its earnings results on Wednesday, August 12th. The company reported $0.74 EPS for the quarter, missing the consensus estimate of $0.76 by ($0.02). The company had revenue of $171.68 million for the quarter, compared to the consensus estimate of $168.48 million. Liquidia had a return on equity of 149.65% and a net margin of 30.74%. The business’s quarterly revenue was up 1842.1% on a year-over-year basis. During the same period in the previous year, the firm posted ($0.49) EPS. Equities analysts forecast that Liquidia Corporation will post 2.05 EPS for the current year.

Liquidia News Roundup

Here are the key news stories impacting Liquidia this week:

• Positive Sentiment: Liquidia settled all six patent and antitrust disputes with United Therapeutics for a net $380.7 million, allowing continued commercialization of YUTREPIA for pulmonary arterial hypertension. Ending the litigation removes significant legal uncertainty and avoids a potentially market-disrupting appeal. Liquidia shares surge as settlement ends United Therapeutics litigation
• Positive Sentiment: Analyst sentiment improved after the settlement. LifeSci Capital upgraded LQDA to “outperform” with a $59 price target, while HC Wainwright raised its target to $65 and initiated or reiterated a “buy” rating. BTIG also upgraded the stock to “buy” with a $70 target. LifeSci Capital upgrades Liquidia
• Positive Sentiment: Preliminary third-quarter YUTREPIA net product sales were reported at $222.7 million. Management expects existing cash and ongoing sales to fund the settlement and planned clinical programs without requiring additional financing, supporting the investment case if commercial momentum continues.
• Positive Sentiment: Trading activity reflected renewed speculative interest, with call-option volume more than doubling its typical level. This suggests some traders are positioning for additional gains following the legal resolution.
• Neutral Sentiment: Multiple executives and insiders, including the CEO and CFO, sold shares at $28.48 under pre-arranged Rule 10b5-1 plans to cover tax obligations on vested equity awards. Because the transactions were planned and sellers retained substantial holdings, they are a limited standalone signal of sentiment. Liquidia insider sale filing
• Negative Sentiment: The $380.7 million settlement will require $175 million within 30 business days, $145.4 million in 2027 installments and $60.3 million tied to antitrust litigation. These payments could materially reduce Liquidia’s cash cushion and constrain future investment.
• Negative Sentiment: Liquidia agreed not to appeal the infringement ruling and will remove the PH-ILD indication from YUTREPIA’s label, narrowing the drug’s addressable market. Needham lowered its price target to $58, despite maintaining a “buy” rating, highlighting ongoing execution and valuation risks.

Institutional Inflows and Outflows

Large investors have recently added to or reduced their stakes in the company. Quantinno Capital Management LP lifted its holdings in shares of Liquidia by 3.6% during the first quarter. Quantinno Capital Management LP now owns 17,165 shares of the company’s stock worth $648,000 after buying an additional 589 shares in the last quarter. Arizona State Retirement System boosted its position in shares of Liquidia by 5.4% in the second quarter. Arizona State Retirement System now owns 17,627 shares of the company’s stock valued at $1,405,000 after acquiring an additional 900 shares during the period. Swiss National Bank boosted its position in shares of Liquidia by 1.3% in the first quarter. Swiss National Bank now owns 120,400 shares of the company’s stock valued at $4,544,000 after acquiring an additional 1,600 shares during the period. Valmark Advisers Inc. boosted its position in shares of Liquidia by 10.2% in the first quarter. Valmark Advisers Inc. now owns 20,546 shares of the company’s stock valued at $775,000 after acquiring an additional 1,905 shares during the period. Finally, Globeflex Capital L P acquired a new position in shares of Liquidia in the second quarter valued at about $175,000. Institutional investors own 64.54% of the company’s stock.

Wall Street Analyst Weigh In

LQDA has been the subject of several research reports. Wedbush set a $58.00 price objective on shares of Liquidia in a research report on Friday, October 2nd. Wall Street Zen cut Liquidia from a “buy” rating to a “hold” rating in a report on Saturday, October 3rd. BTIG Research upgraded Liquidia from a “neutral” rating to a “buy” rating and set a $70.00 price objective for the company in a report on Wednesday. Piper Sandler set a $129.00 target price on Liquidia in a research report on Friday, July 24th. Finally, Weiss Ratings raised Liquidia from a “sell (d-)” rating to a “hold (c)” rating in a research report on Tuesday, September 22nd. One equities research analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating, four have given a Hold rating and two have issued a Sell rating to the stock. According to data from MarketBeat.com, Liquidia has a consensus rating of “Hold” and a consensus price target of $72.85.

Liquidia Company Profile

Liquidia Corporation is a biopharmaceutical company focused on developing and commercializing therapies for patients with serious cardiopulmonary diseases and other rare conditions. The company uses its proprietary PRINT technology to engineer drug particles with controlled size, shape and composition, with the goal of improving the delivery and performance of medicines.

Liquidia’s lead product is Yutrepia (treprostinil) inhalation powder, a dry-powder inhaler designed for the treatment of pulmonary arterial hypertension (PAH).